Abstract
Pain Therapeutics 2005: Market Dynamics and Outlook provides detailed analysis
and information concerning the global market for pain therapeutics, R&D
pipelines and company involvement in this field.
About one and a half billion people suffer from moderate to severe chronic
pain worldwide and approximately 50 million Americans suffer with pain. The
value of the pharmaceutical market for pain relief reflects this seeming
worldwide epidemic of pain, with the overall value reaching nearly $23 billion
in 2004.
In this new report, key pain management therapeutics such as Cox-II
inhibitors, opioids, triptans, anticonvulsants and traditional NSAIDs are
discussed in terms of their past, present and future value and the role they
are playing in the effective management of pain.
The dynamics of this market have been altered greatly over the past year. The
troubles surrounding the multi- billion dollar Cox-II class has created a void
in the marketplace. Pain Therapeutics 2005 explains just what the Cox-II
crisis means for the future of pain management and what kinds of opportunities
their failure may present for other classes of pain management medications.
Pain Therapeutics 2005 also analyzes the markets and provides forecasts for:
- the fast-growing anticonvulsant class
- migraine therapies
- traditional NSAIDs
- and opioids.
This 249-page report also includes the following features:
- 93 tables/graphs which provide the reader with valuable illustrated
insight into trends and issues affecting this growing market.
- Thorough financial breakdown of the leading products and companies making
an impact on the pain market
- Identification and discussion of trends and issues that are pushing the
market into the future.
- Profiles of key companies involved in the development and marketing of
pain therapeutics
- Forecasts of key products/classes
View Cart
